NovaBay Pharmaceuticals Launches Online Sales of CelleRx® Skin Cleanser for Post-Aesthetic Dermatology & Cosmetic Surgery Pr...
November 04 2019 - 06:50AM
Business Wire
Prescription-strength CelleRx to gently clean
skin and ease post-procedure discomfort is now available without a
prescription at www.CelleRx.com
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
the availability of full-strength CelleRx for consumer purchase
without a prescription in the U.S. at CelleRx.com. CelleRx is a
skin and wound cleanser based on NovaBay’s proprietary pure
hypochlorous formulation, and is proven to gently clean and ease
discomfort following aesthetic dermatology and cosmetic surgery
procedures.
“We are delighted to make prescription-strength CelleRx
available without a prescription directly to customers through our
new website,” said Justin Hall, NovaBay CEO. “We are entering the
market with a soft launch to test the brand and create awareness,
with more extensive marketing to begin in early 2020.
“CelleRx has all the characteristics of a successful skin and
wound cleanser: it is known to quickly kill bacteria in vitro, it
prevents the build-up of biofilm that can delay wound healing and
it is safe for underlying tissue. We view this as a significant
advantage given that of the 20 wound cleansers we tested, most
lacked two or even all three of these characteristics,” he added.
“Because of its amazing safety profile, CelleRx has applicability
to almost all dermatological treatments, including cosmetic laser
surgeries, laser resurfacing, chemical peels, liposuction, tattoo
removal, laser hair removal and microdermabrasion.”
CelleRx is based on Neutrox®, the same pure hypochlorous acid
formulation as NovaBay’s flagship product Avenova®, which is proven
to treat the underlying cause of blepharitis and bacterial dry eye.
CelleRx has been cleared as a medical device by the U.S. FDA and
has CE Marking in the EU. Hypochlorous acid is a natural agent
produced by white blood cells as a function of the innate immune
system. In solution, hypochlorous acid kills both gram-negative and
gram-positive bacteria, as well as fungi and biofilms within
seconds. CelleRx is well tolerated and in vitro studies show it
quickly neutralizes super antigens (toxins) and pro-inflammatory
cytokines without interfering with the growth of underlying new
tissue. Safe and effective, CelleRx is non-irritating, reduces
redness and swelling, doesn’t dry or stain skin when applied and
does not generate antibiotic resistance.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our business strategies and future
focus, the launch of a new product and the impact it may have on
our future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, potential uses of our product, market acceptance, and any
potential regulatory problems. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-Q/K
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s progress Like us on Facebook Follow
us on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191104005160/en/
NovaBay Contact Justin Hall
President and Chief Executive Officer 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2023 to Mar 2024